Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4751572 | 0.90 | CYP1A2 (0.33) | CYP1A2CYP2D6 | |
| SCHEMBL20695818 | 0.81 | CYP1A2 (0.39) | CYP1A2CYP2D6ALDH1A1 | |
| SCHEMBL4753749 | 0.80 | — | — | |
| SCHEMBL7734590 | 0.75 | CYP1A2 (0.49) | CYP1A2CYP2D6ALDH1A1 | |
| SCHEMBL4277731 | 0.75 | CYP1A2 (0.49) | CYP1A2CYP2D6ALDH1A1 | |
| SCHEMBL2379725 | 0.75 | CYP1A2 (0.49) | CYP1A2CYP2D6ALDH1A1 | |
| SCHEMBL3536905 | 0.75 | CYP1A2 (0.41) | CYP1A2CYP2D6ALDH1A1 | |
| SCHEMBL28038137 | 0.75 | CYP1A2 (0.41) | CYP1A2CYP2D6ALDH1A1 | |
| SCHEMBL7880507 | 0.75 | CYP1A2 (0.41) | CYP1A2CYP2D6ALDH1A1 | |
| SCHEMBL7735125 | 0.75 | CYP1A2 (0.49) | CYP1A2CYP2D6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE31342-E | STABILIZERS FOR POLYMERS | CIBA-GEIGY CORPORATION (US) | 1983-08-09 | — | — | US | claimed |
| WO-2021195723-A1 | \"METHODS FOR TREATMENT OF CORONAVIRUS INFECTIONS\ | THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH (AU) | 2021-10-07 | — | — | WO | disclosed |
| US-20210186905-A1 | ENHANCING T-CELL FUNCTION AND TREATING A T-CELL DYSFUNCTIONAL DISORDER WITH A COMBINATION OF AN LSD INHIBITOR AND A PD-1 BINDING ANTAGONIST | EPIAXIS THERAPEUTICS PTY LTD (AU) | 2021-06-24 | — | — | US | disclosed |
| US-20210121496-A1 | METHODS AND COMPOSITIONS FOR MODULATING CANCER STEM CELLS | EpiAxis Therapeutics Pty Ltd. (AU) | 2021-04-29 | — | — | US | disclosed |
| EP-3716963-A1 | ENHANCING T-CELL FUNCTION AND TREATING A T-CELL DYSFUNCTIONAL DISORDER WITH A COMBINATION OF AN LSD INHIBITOR AND A PD1 BINDING ANTAGONIST | Epiaxis Therapeutics Pty Ltd (AU) | 2020-10-07 | — | — | EP | disclosed |
| US-20200289437-A1 | Compositions for Modulating Cancer Stem Cells and Uses Therefor | EpiAxis Therapeutics Pty Ltd. (AU) | 2020-09-17 | — | — | US | disclosed |
| CN-111655247-A | Enhancing T cell function and treating T cell dysfunction disorders with a combination of a LSD inhibitor and a PD1 binding antagonist | 艾比克斯治疗私人有限公司 | 2020-09-11 | — | — | CN | disclosed |
| CN-110312522-A | - 1 inhibitor of lysine specific histone demethylation enzyme and application thereof | 堪培拉大学 | 2019-10-08 | — | — | CN | disclosed |
| US-20190262377-A1 | METHODS AND COMPOSITIONS FOR MODULATING CANCER STEM CELLS | EpiAxis Therapeutics Pty Ltd. (AU) | 2019-08-29 | — | — | US | disclosed |
| EP-3509627-A1 | LYSINE SPECIFIC HISTONE DEMETHYLASE-1 INHIBITORS AND USES THEREFOR | University of Canberra (AU) | 2019-07-17 | — | — | EP | disclosed |
| US-20050130941-A1 | Methods of treating alzheimer's disease | PHARMACIA & UPJOHN COMPANY LLC | 2005-06-16 | — | — | US | disclosed |
| EP-1392315-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002100410-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| CN-1054598-C | Pharmacologically active hydrazine derivatives and processes for preparation thereof | NORVATIS CO (CH) | 2000-07-19 | — | — | CN | disclosed |
| US-5753652-A | Antiretroviral hydrazine derivatives | NOVARTIS CORPORATION (US) | 1998-05-19 | — | — | US | disclosed |
| EP-0521827-B1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA GEIGY AG (CH) | 1996-09-25 | — | — | EP | disclosed |
| CN-1068333-A | Has hydrazine analog derivative of pharmacologically active and preparation method thereof | CIBA GEIGY AG (CH) | 1993-01-27 | — | — | CN | disclosed |
| EP-0521827-A1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA-GEIGY AG (CH) | 1993-01-07 | — | — | EP | disclosed |
| US-4631272-A | N-acylated 1-alkylamino-1-deoxy-ketose derivatives, a process for their preparation and their use | BAYER AKTIENGESELLSCHAFT (DE) | 1986-12-23 | — | — | US | disclosed |
| EP-0152856-A2 | N-acylated 1-alkylamimo-1-desoxy ketose derivatives, method for their preparation and use | BAYER AG (DE) | 1985-08-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190262377-A1 | METHODS AND COMPOSITIONS FOR MODULATING CANCER STEM CELLS | BMI1, KDM1B, KDM6B | CYP1A2 4567/4885CYP2D6 4826/4885ALDH1A1 302/4885 |
| US-20050130941-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, BACE2 | CYP1A2 1864/4885CYP2D6 3661/4885ALDH1A1 889/4885 |
| US-20210186905-A1 | ENHANCING T-CELL FUNCTION AND TREATING A T-CELL DYSFUNCTIONAL DISORDER WITH A COMBINATION OF AN LSD INHIBITOR AND A PD-1 BINDING ANTAGONIST | PDCD1, CD274, PDCD1LG2 | CYP1A2 1176/4885CYP2D6 1526/4885ALDH1A1 1890/4885 |
| US-20200289437-A1 | Compositions for Modulating Cancer Stem Cells and Uses Therefor | PRKCQ, PRKCG, PRKCH | CYP1A2 4527/4885CYP2D6 4561/4885ALDH1A1 1880/4885 |
| US-20210121496-A1 | METHODS AND COMPOSITIONS FOR MODULATING CANCER STEM CELLS | BMI1, KDM1B, KDM6B | CYP1A2 4567/4885CYP2D6 4826/4885ALDH1A1 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.